echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Research progress on ASCT pretreatment protocols for IMS 2022 Express MM patients

    Research progress on ASCT pretreatment protocols for IMS 2022 Express MM patients

    • Last Update: 2022-09-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    Comparison of BUMEL and MEL200 in ASCT in patients previously treated with bortezomib, lenalidomide and dexamethasone in NDMM patients most of the data on myeloablative pretreatment protocols were based on data registries, observational studies, clinical experience, and Phase I/II clinical trials


    Figure 1


    Of the 458 initial patients, 396 received ASCT (BUMEL n=202, MEL200 n=194).



    Figure 2


    Figure 3


    Figure 4


    Figure 5


    Figure 6


    References:

    1.


    2.



    Edit: Moly Reviewer: Mia Typography: Moly Executive: Wenting



    Poke "Read the original article" to see more

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.